As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

The National Academy of Sports Medicine® (NASM), the global leader in fitness and wellness training and certifications, is launching its latest course, "Understanding Weight Loss Medications: A Guide ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

How much is Green Impact Partners Inc stock worth? Invest with precise valuations. Get Report.

Anaesthetists are also advised to “consider the potential risk of aspiration within their risk assessment of patients being treated with GLP-1 or dual glucose dependent insulinotropic peptide receptor ...

Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) drug. You inject the drug into your stomach, thigh, or upper arm.

Topline results from our Phase 2 BMT-801 'signal detection' clinical study with MC4R agonist bremelanotide plus a glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist ...